<DOC>
	<DOCNO>NCT01355783</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment E7777 combination CHOP superior efficacy compare CHOP alone improve complete response rate ( CRR ) first line treatment subject Peripheral T-cell Lymphoma ( PTCL ) .</brief_summary>
	<brief_title>A Phase 3 Trial E7777 Combination With CHOP Compared With CHOP Alone First-Line Treatment Peripheral T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>Inclusion : Subjects must meet follow criterion include study : 1 . Local pathologic diagnosis PTCL follow histology type : PTCL , otherwise specify ( PTCLNOS ) , angioimmunoblastic Tcell lymphoma ( AITL ) , anaplastic large cell lymphoma ( ALCL ) ( ALKnegative ALKpositive IPI ≥ 2 ) . 2 . Stage II , III IV disease . 3 . Tumor lesion ( ) measurable 2 dimension compute tomography ( CT ) least 20 mm long transverse dimension nonlymph node mass least 20 mm long transverse dimension lymph node . Subcutaneous mass use indicator lesion . If lesion previously irradiate , must progress prior randomization ( investigator assessment ) use measurable lesion . 4 . Tumor biopsy available central pathologic review ; may archive sample prior biopsy within 6 month study enrollment , sample obtain study screen . 5 . Age ≥ 18 year . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 7 . Adequate bone marrow reserve evidence : absolute neutrophil count ( ANC ) ≥ 1000/mm3 ( 1.0x109/L ) platelet ≥ 50,000/mm3 ( 50x109/L ) ; ( ≥ 25,000/mm3 [ 25x109/L ] allow thrombocytopenia secondary bone marrow involvement lymphoma ) hemoglobin ≥ 8 g/dL ( 80 g/L ) 8 . Adequate liver function evidence : bilirubin ≤ 1.5 time upper limit normal ( ULN ) aspartate aminotransferase ( AST [ SGOT ] ) alanine aminotransferase ( ALT [ SGPT ] ) ≤ 3 time ULN ( ≤ 5 time ULN hepatic involvement ) albumin ≥ 3.0 g/dL ( 30 g/L ) 9 . Adequate renal function evidence serum creatinine ≤ 2.0 mg/dL ( 176 μmol/L ) calculate creatinine clearance ≥ 40 mL/min per CockcroftGault formula . 10 . Willing able comply aspect protocol . 11 . Written inform consent prior studyspecific screening procedure . 12 . Female subject childbearing potential must negative serum betahuman chorionic gonadotropin ( βhCG ) pregnancy test Screening negative serum urine βhCG pregnancy test result Baseline , must agree use highly effective method contraception ( see protocol list ) throughout entire study period 30 day study drug discontinuation . 13 . Male subject partner woman childbearing potential must use partner must use highly effective method contraception ( see protocol list ) begin least 1 menstrual cycle prior start study drug ( ) , throughout entire study period , 30 day study drug discontinuation , unless sexually abstinent undergone successful vasectomy . Those partner use hormonal contraceptive must also use additional approve method contraception , describe previously . Exclusion : Subjects meet follow criterion exclude study : 1 . Diagnosis ALCL ALKpositive IPI 0 1 , adult Tcell leukemia/lymphoma ( ATLL ) , precursor Tcell lymphoblastic lymphoma/leukemia , extranodal NK/TCL nasal type , enteropathyassociated TCL , hepatosplenic TCL , subcutaneous panniculitislike TCL , cutaneous Tcell lymphoma ( CTCL ) include mycosis fungoides Sezary syndrome . 2 . Known central nervous system ( CNS ) involvement lymphoma . 3 . Prior chemotherapy , immunotherapy , denileukin diftitox , investigational agent ( ) lymphoma , exception single cycle CHOP ( CHOPbased therapy ) allow last dose CHOP ( CHOPbased therapy ) administer ≤ 28 day study enrollment ( LeadIn ) randomization ( Main Study ) . 4 . Prior radiotherapy lymphoma , follow exception : prior radiation therapy localize disease ≥ 4 week randomization allow long irradiated area mediastinal area site potentially measurable disease . 5 . Prior malignancy within past 5 year ( except nonmelanoma skin cancer carcinoma situ cervix ) . 6 . Serious intercurrent illness . 7 . Significant cardiac disease require ongoing treatment , include congestive heart failure ( CHF ) , severe coronary artery disease ( CAD ) , cardiomyopathy , uncontrolled cardiac arrhythmia , unstable angina pectoris , myocardial infarction ( MI ) ( within 6 month study enrollment ) . 8 . Left ventricular ejection fraction ( LVEF ) less institutional low limit normal , determine multigated acquisition scan ( MUGA ) echocardiogram . 9 . Major surgery within 2 week study enrollment . 10 . Active infection require specific antiinfective therapy . 11 . Known human immunodeficiency virus ( HIV ) infection ; know active hepatitis B hepatitis C infection . 12 . Deep vein thrombosis within 3 month study enrollment . 13 . Females pregnant ( positive urine test ) breastfeeding . 14 . Any history concomitant medical condition , opinion Investigator , would compromise subject 's ability safely complete study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>